The TAPUR Study is designed to evaluate molecularly targeted cancer drugs and collect data on clinical outcomes to learn about potential additional uses of these drugs outside of Food and Drug Administration (FDA) approved indications. It provides a clinical trial opportunity for patients with advanced cancer with tumors that have genomic alterations that can be targeted with a TAPUR Study drug.
TAPUR is sponsored by the American Society of Clinical Oncology (ASCO), which represents nearly 45,000 oncology professionals around the world who care for people living with cancer. ASCO works to conquer cancer through research, education, and promotion of the highest quality and equitable patient care.
MCGI Brings TAPUR Study to the Northeast
The TAPUR Study is available in a number of largely urban community-based oncology practices, and with this collaboration, JAX will enable Maine and New Hampshire to join the TAPUR Study as the first rural states in the Northeast at a statewide level. The TAPUR Study is now enrolling patients at the following locations as part of MCGI:
Maine Health — Maine Medical Center
MaineGeneral Medical Center — Harold Alfond Center for Cancer Care
New England Care Specialists
New Hampshire Oncology-Hematology
Northern Light Health
The TAPUR Study is now enrolling. Visit the TAPUR website at tapur.org or email MCGI@jax.org for more information.